To support future product claims, Redwood Pharma is conducting a single-center trial led by Prof. Gerhard Garhöfer who states, "We are excited to start this trial at the Medical University of Vienna, Austria. Dry eye is a disease with many sufferers and where new treatments are needed. As a unique thermogel, RP501 has the potential of providing relief to many. "

60 patients will be divided into groups to assess the safety and efficacy in patients with and without contact lenses. Treatment duration will vary between patient groups where one group will be treated over a month and another over three months. Results of the trial will be used to support a CE-mark, as well as other regulatory market clearances. Furthermore, the results will serve as an important platform in the next commercial phase. With this approval, Redwood Pharma can begin including patients shortly.

"We are very happy to receive this approval from the Austrian authority with the help of our partnering CRO and Prof. Garhöfer. This trial represents the next step in the development and commercialization of RP501, which we strongly believe can help provide therapeutic relief to dry eye sufferers. As we have already seen the significant effects of RP501 in the company's Phase II trial, we anticipate strong commercial potential of this new product," says CEO Martin Vidaeus.

This disclosure contains information that Redwood Pharma is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 28-03-2022 15:15 CET.